a validated technology platform
Our virosome vaccine technology and know-how has been validated through high value partnerships and collaboration with some of the world’s leading research funding organizations.
Our delivery platform is being validated through partnership with leading pharmaceutical or research organisations, including Astellas Pharma, PATH-MVI and the Bill and Melinda Gates Foundation.
Early 2014, our RSV virosome vaccine and technology was selected by Astellas – ClearPath as the most promising RSV vaccine for the Astellas vaccine franchise targeting infectious diseases. Following a thorough due diligence of Mymetics’ virosome IP, know-how and the RSV virosome vaccine preclinical results and construct, we signed an exclusive license and collaboration agreement for our RSV virosome based vaccine funded by Astellas, a leading Japanese pharma company.
On January 29, 2016 Mymetics announced that the collaboration agreement will be discontinued, with effective date July 25, 2016.
Mymetics is currently evaluating new possible partnerships around the RSV virosome vaccine IP, know-how and deep expertise that has been build during this collaboration.
In close cooperation with the Texas Biomedical Research Institute, our HIV vaccine candidate obtained funding from the Bill & Melinda Gates Foundation to perform a study in non-human primates, replicating a smaller study in which the vaccine provided an unprecedented 100% protection in macaque monkeys. The Mymetics’ HIV vaccine is the first with a demonstrated ability to prevent viral transmission in primates.
Our virosome technology has been selected by PATH-MVI, the world leading malaria vaccine research funding organization, to develop a transmission blocking malaria vaccine based on the antigens of LMIV (NIAID-NIH).
Since April 2015, Mymetics is leading a project with a consortium of companies which have been awarded a total of €8.4 million in grant financing.
The innovation project has as objective to develop cold-chain independent and thermo stable virosome vaccines. The project will receive €5.3 million funding from the European Union’s Horizon 2020 research and innovation programme under Grant Agreement No 646122. and €3.1 million from the Swiss Secretariat for Education, Research and Innovation.
More than 30 years of experience in the field of virosome vaccines, a unique R&D expertise, and intellectual property rights, makes Mymetics the global leader in this field. A focused strategy based on a sound scientific approach have resulted in the development a rich pipeline of vaccine candidates...Read more
Few companies in the world have developed such a powerful technology platform and a unique know-how to develop next-generation prophylactic vaccines for infectious diseases...Read more